Monument to Alfonso XII of Spain in Retiro Park, Madrid, Spain.

ESMO 2017 Congress took place September 8-12 in Madrid, Spain.

Antibody shows early promise in AML/MDS trial

Print Friendly, PDF & Email


Micrograph showing MDS
Interim results of a phase 1 study suggest flotetuzumab, a CD123 and CD3 bispecific antibody, may be a feasible treatment option for relapsed or refractory acute myeloid leukemia (AML) or intermediate/high-risk myelodysplastic syndromes (MDS). Researchers said flotetuzumab demonstrated acceptable tolerability in the dose-escalation portion of the study, with infusion-related reactions... [Read Article]
Print Friendly, PDF & Email

Survey reveals lack of specialized care for AYAs with cancer

Print Friendly, PDF & Email


Doctor consults with cancer
patient and her father
Photo by Rhoda Baer
New research indicates there is a lack of specialized care in Europe for adolescents and young adults (AYAs) with cancer. In a survey of more than 200 European healthcare professionals, more than two-thirds of respondents said they did not have access... [Read Article]
Print Friendly, PDF & Email

Biosimilar deemed equivalent to reference drug in FL

Print Friendly, PDF & Email


Vials of drug
Photo by Bill Branson
The biosimilar GP2013 has demonstrated equivalence to its reference drug rituximab in patients with previously untreated, advanced-stage follicular lymphoma (FL), according to researchers. Treatment with GP2013 plus cyclophosphamide, vincristine, and prednisone (CVP) produced a similar overall response rate (ORR) as rituximab plus CVP in the phase... [Read Article]
Print Friendly, PDF & Email

Treatment for WDTC tied to increased risk of AML

Print Friendly, PDF & Email


Session at ESMO 2017
Photo courtesy of ESMO
New research suggests patients with well-differentiated thyroid cancer (WDTC) are more likely to develop acute myeloid leukemia (AML) if they receive radioactive iodine (RAI) after surgery. Of the WDTC patients studied, those who only underwent surgery were less likely to develop AML. WDTC patients who... [Read Article]
Print Friendly, PDF & Email

Study: Many cancer patients don’t understand clinical trials

Print Friendly, PDF & Email


Preparing drug for a trial
Photo by Esther Dyson
Results of a nationwide study suggest many cancer patients in Ireland don’t understand key aspects of clinical trial methodology. Most of the patients surveyed, which included individuals who had participated in a clinical trial, did not understand the concepts of randomization or equipoise. “Over... [Read Article]
Print Friendly, PDF & Email